Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 6, 2015, Pages 1075-1084

  Murakawa, Miyako ^a   Asahina, Yasuhiro ^a   Nakagawa, Mina ^a   Sakamoto, Naoya ^b   Nitta, Sayuri ^a   Kusano Kitazume, Akiko ^a   Watanabe, Takako ^a   Kawai Kitahata, Fukiko ^a   Otani, Satoshi ^a   Taniguchi, Miki ^a   Goto, Fumio ^a   Nishimura Sakurai, Yuki ^a   Itsui, Yasuhiro ^a   Azuma, Seishin ^a   Kakinuma, Sei ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C virus; NS3 protease inhibitor; Pegylated interferon; Peripheral blood mononuclear cells; Type III interferon

Indexed keywords

ALPHA INTERFERON; CYTOKINE; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA 4; INTERLEUKIN 28B; MESSENGER RNA; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEINASE INHIBITOR; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENOTYPE; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; ALLELE; BIOSYNTHESIS; DRUG RESISTANCE; GENETICS; HEPATITIS C, CHRONIC; PHYSIOLOGY;

ADULT; AGED; ALLELES; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER;

EID: 84928317740     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12902     Document Type: Article

References (35)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65.
2. Ghany MG, Strader DB, Thomas DL etal. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
3. Ghany MG, Nelson DR, Strader DB etal. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
4. Forestier N, Zeuzem S. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver Int. 2012; 32 (Suppl 1): 44-50.
5. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
6. Ge D, Fellay J, Thompson A etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
7. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.
8. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in il28b is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
9. Kotenko S. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev. 2002; 13: 223-240.
10. Sheppard P, Kindsvogel W, Xu W etal. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003; 4: 63-68.
11. Osterlund P, Pietilae T, Veckman V etal. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J. Immunol. 2007; 179: 3434-3442.
12. Ank N, Iversen M, Bartholdy C etal. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 2008; 180: 2474-2485.
13. Ank N, West H, Bartholdy C etal. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006; 80: 4501-4509.
14. Marcello T, Grakoui A, Barba-Spaeth G etal. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
15. Dolganiuc A, Kodys K, Marshall C etal. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS ONE 2012; 7: e44915.
16. Li M, Liu X, Zhou Y etal. Interferon-lambda s: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol. 2009; 86: 23-32.
17. Asahina Y, Nakagawa M, Kakinuma S etal. Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response. J. Clin. Transl. Hepatol. 2013; 1: 39-44.
18. Asahina Y, Izumi N, Hirayama I etal. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology 2008; 134: 1396-1405.
19. Asahina Y, Tsuchiya K, Muraoka M etal. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 2012; 55: 20-29.
20. Sarasin-Filipowicz M, Oakeley EJ, Duong FH etal. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. U.S.A. 2008; 105: 7034-7039.
21. Prokunina-Olsson L, Muchmore B, Tang W etal. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013; 45: 164-171.
22. Amanzada A, Kopp W, Spengler U etal. Interferon-λ4 (IFNL4) Transcript Expression in Human Liver Tissue Samples. PLoS ONE 2013; 8: e84026.
23. Sakamoto N, Nakagawa M, Tanaka Y etal. Association of IL28B Variants With Response to Pegylated-Interferon Alpha Plus Ribavirin Combination Therapy Reveals Intersubgenotypic Differences Between Genotypes 2a and 2b. J. Med. Virol. 2011; 83: 871-878.
24. Aly H, Watashi K, Hijikata M etal. Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. J. Hepatol. 2007; 46: 26-36.
25. Tasaka M, Sakamoto N, Nakagawa M etal. Hepatitis C virus non-structural proteins responsible for suppression of the RIG-I/Cardif-induced interferon response. J. Gen. Virol. 2007; 88: 3323-3333.
26. Nakagawa M, Sakamoto N, Tanabe Y etal. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-1041.
27. Onoguchi K, Yoneyama M, Takemura A etal. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 2007; 282: 7576-7581.
28. Langhans B, Kupfer B, Braunschweiger I etal. Interferon-lambda serum levels in hepatitis C. J. Hepatol. 2011; 54: 859-865.
29. Murata K, Sugiyama M, Kimura T etal. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients. J. Gastroenterol. 2014; 49: 126-137.
30. Stone AE, Giugliano S, Schnell G etal. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 2013; 9: e1003316.
31. Thomas E, Gonzalez VD, Li Q etal. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978-988.
32. Makowska Z, Heim M. Interferon signaling in the liver during hepatitis C virus infection. Cytokine 2012; 59: 460-466.
33. Booth D, George J. Loss of function of the new interferon IFN-lambda 4 may confer protection from hepatitis C. Nat. Genet. 2013; 45: 119-120.
34. Lupberger J, Felmlee DJ, Baumert TF. Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. Hepatology 2013; 58: 439-441.
35. Yoshio S, Kanto T, Kuroda S etal. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology 2013; 57: 1705-1715.